Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group
Guilhot, F.
Seminars in Hematology 30(3 Suppl 3: 24-25
1993
ISSN/ISBN: 0037-1963 PMID: 8235700 Document Number: 413251
Document emailed within 1 workday
Related Documents
Guilhot, F.; Guerci, A.; Fiere, D.; Harousseau, J.L.; Maloisel, F.; Bouabdallah, R.; Guyotat, D.; Rochant, H.; Najman, A.; Nicolini, F.; Colombat, P.; Abgrall, J.F.; Ifrah, N.; Brière, J.; Bauters, F.; Navarro, M.; Morice, P.; Bordessoule, D.; Vilque, J.P.; Desablens, B.; Tertian, G.; Blanc, M.; Chastang, C.; Tanzer, J. 1996: The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group Bone Marrow Transplantation 17(Suppl 3): S29-S31Takemoto, Y.; Sampi, K.; Kuraishi, Y.; Okabe, K.; Tamura, K.; Mizoguchi, H.; Saito, H.; Masaoka, T.; Ogawa, M. 1999: A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. the KRN8602 Leukemia Study Group International Journal of Hematology 70(1): 20-25
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J. 1985: High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group Seminars in Oncology 12(2 Suppl 3: 117-119
Guilhot, F. 1994: The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase Nouvelle Revue Francaise d'Hematologie 36(Suppl 1): S39-S46
Opalka, B.; Wandl, U.; Beer, U.; Roggenbuck, U.; Kloke, O.; Niederle, N. 1991: Breakpoint localization within the M-bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy Leukemia 5(6): 452-456
Ezaki, K. 2000: Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 279-284
Morra, E.; Alimena, G.; Lazzarino, M.; Liberati, A.M.; Montefusco, E.; Bernasconi, P.; Mancini, M.; Donti, E.; Merante, S.; Caricchi, P. 1993: Evolving approaches with interferon alfa in chronic myelogenous leukemia Seminars in Hematology 30(3 Suppl 3: 26-27
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274
Wysocki, M.; Nowaczyk-Michalak, A.; Pilecki, O.; Trybuś, L.; Balcar-Boroń, A. 1992: Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia Acta Haematologica Polonica 23(3): 197-199
Vogler, W.R.; Velez-Garcia, E.; Omura, G.; Raney, M. 1989: A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia Seminars in Oncology 16(1 Suppl 2: 21-24
Armenta, D.; Espallargas, C.; Paz, A.; Rodríguez Martorel, J.; Ladines, R.; Alvarez, C.; Román, J.; Andrés, P. 1996: Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan Sangre 41(6): 465-467
Fernández, I.; Castellano, G.; Canga, F.; Colina, F.; García, H.; Fuertes, A.; Casis, B.; Martín, A.; Solís, J.A. 1995: A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C Gastroenterologia y Hepatologia 18(2): 66-72
Cannistra, S.A.; Groshek, P.; Griffin, J.D. 1989: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia Leukemia 3(5): 328-334
Nemet, D.; Labar, B.; Bogdanić, V.; Hauptman, E.; Jaksić, B.; Minigo, H.; Sertić, D.; Mrsić, M.; Pavletić, Z.; Kovacević, J. 1989: High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia Bone Marrow Transplantation 4(Suppl 3): 42-44
Tóthová, E.; Stecová, N.; Kafková, A.; Fricová, M.; Svorcová, E. 2002: Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa Vnitrni Lekarstvi 48(5): 380-383
Fukuhara, T.; Miyake, T.; Maekawa, I.; Kurosawa, M.; Suzuki, S.; Noto, S.; Mori, A.; Chiba, K.; Toyoshima, T.; Hirano, T.; Morioka, M.; Tsutsumi, Y.; Okabe, M.; Kakinoki, Y. 2000: Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study International Journal of Hematology 71(4): 366-371
Klener, P.; Háber, J. 1985: Treatment of refractory leukemia with high-dose cytosine arabinoside Neoplasma 32(1): 113-117
Pedersen, G.; Stentoft, J.; Pedersen, J.O.; Jensen, M.K. 1994: Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside Ugeskrift for Laeger 156(43): 6380-6384
Urabe, A.; Asano, S.; Mizoguchi, H.; Aoki, N.; Takaku, F. 2000: Long-term follow up of chronic myelogenous leukemia patients treated with natural interferon alpha--multi-institutional cooperative study Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(10): 1541-1546
Meloni, G.; Russo, D.; Baccarani, M.; Testoni, N.; Martinelli, G.; Fanin, R.; Zuffa, E.; Rosti, G.; Alimena, G.; Saglio, G.; Mandelli, F.; Tura, S. 1999: A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. the Italian Co-operative Study Group on Chronic Myeloid Leukemia Haematologica 84(8): 707-715